Nine papers published simultaneously across the Nature family of journals lay out a molecular map of Alzheimer's disease, Parkinson's disease, schizophrenia and other brain disorders, drawn from human brain tissue analyzed one cell at a time. The work comes from the PsychAD Consortium, a multidisciplinary effort led by Mount Sinai scientists and supported by the National Institute on Aging since its launch in 2019.
The collection includes three papers in Nature, three in Nature Communications, and one each in Nature Medicine, Nature Genetics and Scientific Data. Taken together, the consortium describes it as one of the largest applications of single-cell genomics yet attempted in human brain disease, producing data resources meant to be used by other laboratories rather than just to answer one question.
What distinguishes the effort is breadth. Single-cell studies in psychiatry and neurodegeneration have mostly been small, or built around a single diagnosis, which makes it hard to tell whether a molecular change is specific to Alzheimer's or common to brain disease generally. By examining multiple conditions side by side at single-cell resolution, the investigators report both shared and disease-specific changes tied to neurodegeneration, psychiatric illness and cognitive decline. As the researchers put it, no one has systematically examined how molecular mechanisms overlap across different brain disorders at this scale.
For patients and families, nothing here changes clinical practice. The value is upstream: identifying which cell types and molecular pathways are involved, and which are shared across diagnoses, is the step that tells drug developers where to aim. Resources of this kind tend to pay off over years, as other groups mine the data for targets and biomarkers.